PCR Gains New Powers and Broadens Its Clinical Remit
Already indispensable as a means of diagnosing COVID-19, PCR has the speed, sensitivity, and reliability to take on a wide range of clinical applications.
Related Articles
ASGT 2024: Gene Therapy Delivery and Development Dominates Opening Workshop
In one of the opening workshops at ASGCT 2024, topics around delivery methods for gene therapies and approaches to expand the gene editing toolbox dominated…
Boy Dosed with Pfizer DMD Gene Therapy Dies a Year after Phase II Trial
Pfizer has paused enrollment in a Phase III trial assessing its Duchenne muscular dystrophy (DMD) gene therapy candidate fordadistrogene movaparvovec after acknowledging the sudden death…
Online Event
Developing a biosimilar drug requires screening many samples originating from different cell lines to select the most appropriate ones for further process development. Each sample…
Neural Compass May Lead to Insights into Parkinson’s and Alzheimer’s Diseases
Internal neural compass which the human brain uses to orientate itself in space and navigate through the environment has been identified.
Solvias to Build New Biologics and CGT Testing Center in North Carolina
Solvias says its new center complements its biologics and CGT sites in Europe and expands its testing capabilities in the United States.
Broken String-Crick Institute Collaboration Focuses on ALS Research
The Crick Institute plans to leverage Broken String’s DNA break-mapping platform to develop novel applications for ALS treatments.
Viral Advantage: Prologue Medicines is Here to Release the Viral Proteome’s Therapeutic Potential
Prologue Medicines’ platform combines computation and high-throughput biology to decode millennia of viral evolution.
Court Grants Vizgen Motion to Expand Antitrust Case vs.10x, Harvard
A U.S. District Court judge has granted Vizgen’s motion to expand its antitrust case against rival 10x Genomics and Harvard University.
ASGT 2024: Gene Therapy Delivery and Development Dominates Opening Workshop
In one of the opening workshops at ASGCT 2024, topics around delivery methods for gene therapies and approaches to expand the gene editing toolbox dominated…
Boy Dosed with Pfizer DMD Gene Therapy Dies a Year after Phase II Trial
Pfizer has paused enrollment in a Phase III trial assessing its Duchenne muscular dystrophy (DMD) gene therapy candidate fordadistrogene movaparvovec after acknowledging the sudden death…